MX9702553A - Adenovirus libres de particulas contaminantes viables, su preparacion y su uso. - Google Patents
Adenovirus libres de particulas contaminantes viables, su preparacion y su uso.Info
- Publication number
- MX9702553A MX9702553A MX9702553A MX9702553A MX9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A MX 9702553 A MX9702553 A MX 9702553A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- particle free
- contaminant particle
- viable
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0023—Heat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/04—Heat
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/075—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se relaciona con vectores virales novedosos, derivados de adenovirus, su preparacion y su utilizacion en terapia genética. Se relaciona de manera preferible, con los adenovirus recombinantes que comprenden un genoma de un adenovirus (i) en el que la region E1 está inactivada, (ii) en el que la organizacion genomica está modificada (iii) en el que la recombinacion eventual con el genoma del linaje de produccion conduce a la generacion de partículas virales no viables.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9413355A FR2726285B1 (fr) | 1994-10-28 | 1994-10-28 | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
PCT/FR1995/001415 WO1996013596A1 (fr) | 1994-10-28 | 1995-10-25 | Adenovirus depourvus de particules contaminantes viables, preparation et utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9702553A true MX9702553A (es) | 1997-06-28 |
Family
ID=9468601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9702553A MX9702553A (es) | 1994-10-28 | 1995-10-25 | Adenovirus libres de particulas contaminantes viables, su preparacion y su uso. |
Country Status (13)
Country | Link |
---|---|
US (2) | US6312946B1 (es) |
EP (1) | EP0787199A1 (es) |
JP (1) | JPH10507922A (es) |
KR (1) | KR100424803B1 (es) |
CN (1) | CN1110564C (es) |
AU (1) | AU703539B2 (es) |
FI (1) | FI971783A0 (es) |
FR (1) | FR2726285B1 (es) |
IL (1) | IL115779A0 (es) |
MX (1) | MX9702553A (es) |
NO (1) | NO320090B1 (es) |
WO (1) | WO1996013596A1 (es) |
ZA (1) | ZA959086B (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1548118A2 (en) | 1994-06-10 | 2005-06-29 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
DE69534166T2 (de) * | 1994-10-28 | 2006-03-09 | Trustees Of The University Of Pennsylvania | Rekombinanter adenovirus und methoden zu dessen verwendung |
CA2206683A1 (en) * | 1994-12-12 | 1996-06-20 | Genetic Therapy, Inc. | Improved adenoviral vectors and producer cells |
FR2730504B1 (fr) * | 1995-02-13 | 1997-03-28 | Rhone Poulenc Rorer Sa | Procede de preparation de genomes d'adenovirus recombinants |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
ATE278794T1 (de) | 1995-06-15 | 2004-10-15 | Crucell Holland Bv | Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
FR2748753B1 (fr) * | 1996-05-20 | 1998-08-14 | Transgene Sa | Nouveaux vecteurs adenoviraux pour la therapie genique |
ES2208942T3 (es) * | 1996-07-05 | 2004-06-16 | Philip E. Branton | Proteinas e4 de adenovirus para inducir la muerte celular. |
US6730662B1 (en) | 1996-07-05 | 2004-05-04 | Mcgill University | Adenovirus E4 proteins for inducing cell death |
WO1998010087A1 (en) * | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
FR2755699B1 (fr) * | 1996-11-08 | 1998-12-18 | Rhone Poulenc Rorer Sa | Nouvelles constructions et vecteurs pour l'expression ciblee et inductible des genes |
US5981275A (en) * | 1997-04-14 | 1999-11-09 | Genzyme Corporation | Transgene expression system for increased persistence |
CA2288306A1 (en) | 1997-04-28 | 1998-11-05 | Rhone-Poulenc Rorer S.A. | Adenovirus-mediated intratumoral delivery of an angiogenesis antagonist for the treatment of tumors |
US6696423B1 (en) | 1997-08-29 | 2004-02-24 | Biogen, Inc. | Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
FR2774699B1 (fr) * | 1997-11-17 | 2003-10-03 | Rhone Poulenc Rorer Sa | Methode de reduction des evenements de recombinaison homologue |
EP1199368B1 (en) * | 1998-07-07 | 2004-01-21 | Transgene S.A. | Use of adenoviral e4 reading frames to improve expression of a gene of interest |
US6461869B1 (en) * | 1999-07-20 | 2002-10-08 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Purging leukemia cells from hematopoietic stem cells |
FR2799472B1 (fr) | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
KR101250021B1 (ko) | 2000-05-26 | 2013-04-03 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 완화된 부작용을 갖는 신규 재조합 아데노바이러스 벡터 |
US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
WO2006060089A2 (en) * | 2004-10-25 | 2006-06-08 | Biogen Idec Ma Inc. | Novel methods for producing adenoviral vector preparations with reduced replication-competent adenovirus contamination and novel adenoviral vectors and preparations |
EP2049666A2 (en) | 2006-07-28 | 2009-04-22 | Sanofi-Aventis | Composition and method for treatment of tumors |
WO2012021730A2 (en) * | 2010-08-11 | 2012-02-16 | Genvec, Inc. | Respiratory syncytial virus (rsv) vaccine |
SG187785A1 (en) * | 2010-08-16 | 2013-03-28 | Salk Inst For Biological Studi | Anti-cancer adenoviruses |
WO2014153204A1 (en) | 2013-03-14 | 2014-09-25 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions |
JP7054527B2 (ja) | 2016-02-23 | 2022-04-14 | ソーク インスティテュート フォー バイオロジカル スタディーズ | アデノウイルスの複製動態を測定するための高スループットアッセイ |
JP7015551B2 (ja) | 2016-02-23 | 2022-02-15 | ソーク インスティテュート フォー バイオロジカル スタディーズ | ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現 |
WO2018111767A1 (en) | 2016-12-12 | 2018-06-21 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
CA3062591A1 (en) | 2017-05-08 | 2018-11-15 | Gritstone Oncology, Inc. | Alphavirus neoantigen vectors |
JP2021509823A (ja) | 2018-01-04 | 2021-04-08 | アイコニック セラピューティクス インコーポレイテッド | 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法 |
KR20220016137A (ko) | 2019-05-30 | 2022-02-08 | 그릿스톤 바이오, 인코포레이티드 | 변형된 아데노바이러스 |
JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
JP2023551743A (ja) * | 2021-01-21 | 2023-12-12 | 株式会社 セリッド | 複製能のあるアデノウイルスを包含しない新規アデノウイルスベクター、およびこれの使用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
FR2704234B1 (fr) * | 1993-04-22 | 1995-07-21 | Centre Nat Rech Scient | Virus recombinants, preparation et utilisation en therapie genique. |
FR2705361B1 (fr) * | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
FR2726285B1 (fr) * | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
-
1994
- 1994-10-28 FR FR9413355A patent/FR2726285B1/fr not_active Expired - Fee Related
-
1995
- 1995-10-25 WO PCT/FR1995/001415 patent/WO1996013596A1/fr not_active Application Discontinuation
- 1995-10-25 CN CN95195913A patent/CN1110564C/zh not_active Expired - Fee Related
- 1995-10-25 EP EP95936609A patent/EP0787199A1/fr not_active Withdrawn
- 1995-10-25 MX MX9702553A patent/MX9702553A/es not_active IP Right Cessation
- 1995-10-25 KR KR1019970702755A patent/KR100424803B1/ko not_active IP Right Cessation
- 1995-10-25 JP JP8514357A patent/JPH10507922A/ja not_active Ceased
- 1995-10-25 US US08/817,575 patent/US6312946B1/en not_active Expired - Fee Related
- 1995-10-25 AU AU38477/95A patent/AU703539B2/en not_active Ceased
- 1995-10-26 IL IL11577995A patent/IL115779A0/xx not_active IP Right Cessation
- 1995-10-26 ZA ZA959086A patent/ZA959086B/xx unknown
-
1997
- 1997-04-17 NO NO19971764A patent/NO320090B1/no unknown
- 1997-04-25 FI FI971783A patent/FI971783A0/fi not_active IP Right Cessation
-
2001
- 2001-01-26 US US09/769,352 patent/US6482617B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR100424803B1 (ko) | 2004-06-12 |
NO320090B1 (no) | 2005-10-24 |
US20010039046A1 (en) | 2001-11-08 |
NO971764L (no) | 1997-04-17 |
AU3847795A (en) | 1996-05-23 |
KR970707292A (ko) | 1997-12-01 |
CN1162338A (zh) | 1997-10-15 |
FI971783A (fi) | 1997-04-25 |
US6482617B2 (en) | 2002-11-19 |
JPH10507922A (ja) | 1998-08-04 |
IL115779A0 (en) | 1996-01-19 |
AU703539B2 (en) | 1999-03-25 |
EP0787199A1 (fr) | 1997-08-06 |
ZA959086B (en) | 1996-07-16 |
FR2726285B1 (fr) | 1996-11-29 |
CN1110564C (zh) | 2003-06-04 |
WO1996013596A1 (fr) | 1996-05-09 |
FR2726285A1 (fr) | 1996-05-03 |
FI971783A0 (fi) | 1997-04-25 |
NO971764D0 (no) | 1997-04-17 |
US6312946B1 (en) | 2001-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9702553A (es) | Adenovirus libres de particulas contaminantes viables, su preparacion y su uso. | |
CZ63995A3 (en) | Virus vectors and their use in gene therapy | |
CA2236968A1 (en) | Accessory functions for use in recombinant aav virion production | |
AU5152998A (en) | Improved adenovirus vectors | |
MX9603002A (es) | Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos. | |
PL317234A1 (en) | Vaccines against papilloma virus | |
AU7335296A (en) | Recombinant sendai virus | |
ES2168258T3 (es) | Vectores virales recombinantes que codifican para proteinas de papilomavirus humano. | |
AU681705B2 (en) | Endosomolytically active particles | |
AU2853395A (en) | Recombinant vectors derived from adenovirus for use in gene therapy | |
EP1180932A4 (en) | ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF | |
AUPN477695A0 (en) | Gene therapy | |
MX9705937A (es) | Procedimiento de preparacion de genoma de adenovirus recombinantes. | |
NZ331556A (en) | Parapoxviruses containing foreign DNA, their production and their use in vaccines | |
AU7234987A (en) | Viral vector coding for a glycoprotein of the virus responsible for a.i.d.s., vaccine and antibody | |
AU4307197A (en) | Herpesvirus saimiri as viral vector | |
AU3525095A (en) | Deffective recombinant adenoviruses with inactivated iva2 gene | |
ATE46264T1 (de) | Thymidinkinase-negativ-temperaturbestaendiger rinder herpes-virus-1-mutant als vakzin gegen infektioese rinder-rhinotracheitis. | |
MX9700870A (es) | Virus de herpes recombinante con promotor de gen gb. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |